Skip to main content
. 2019 Nov 11;176(Suppl 1):S297–S396. doi: 10.1111/bph.14752
Nomenclature http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2030
Common abbreviation GSK3B
HGNC, UniProt https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4617, http://www.uniprot.org/uniprot/P49841
EC number http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.26
Inhibitors http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8016 (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/12606497?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7958 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/15267232?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8014 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/12606497?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8015 (pIC50 ~8.1) [http://www.ncbi.nlm.nih.gov/pubmed/11033082?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8018 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/14698171?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8019 (pIC50 ~7.4) [http://www.ncbi.nlm.nih.gov/pubmed/11033082?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8017 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/20708937?dopt=AbstractPlus]
Selective inhibitors http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8478 (pK i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/22489897?dopt=AbstractPlus]
Comments Due to its Tau phosphorylating activity, small molecule inhibitors of GSK‐3β are being investigated as potential treatments for Alzheimer's disease (AD) [http://www.ncbi.nlm.nih.gov/pubmed/22489897?dopt=AbstractPlus]. GSK‐3β also plays a role in canonical Wnt pathway signalling, the normal activity of which is crucial for the maintenance of normal bone mass. It is hypothesised that small molecule inhibitors of GSK‐3β may provide effective therapeutics for the treatment of diseases characterised by low bone mass [http://www.ncbi.nlm.nih.gov/pubmed/22142634?dopt=AbstractPlus].